For the year ending 2025-12-31, FDMT made $85,209K in revenue. -$140,109K in net income. Net profit margin of -164.43%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration and license revenue | 85,209 | 37 | ||
| Research and development (includes 1,322 and 1,005 for the years ended december 31, 2025 and 2024, respectively, attributable to related parties) | 195,696 | 141,299 | ||
| General and administrative | 49,060 | 46,579 | ||
| Total operating expenses | 244,756 | 187,878 | ||
| Loss from operations | -159,547 | -187,841 | ||
| Interest income | 19,475 | 27,050 | ||
| Other expense, net | -37 | -77 | ||
| Total other income, net | 19,438 | 26,973 | ||
| Net loss | -140,109 | -160,868 | ||
| Basic EPS | -2.42 | -2.98 | ||
| Diluted EPS | -2.42 | -2.98 | ||
| Basic Average Shares | 57,930,180 | 53,943,741 | ||
| Diluted Average Shares | 57,930,180 | 53,943,741 | ||
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)